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Center, New York, New York, USA; and 3Northwestern University Comprehensive Transplant Center, Chicago, Illinois, USAIntroduction: Kidney transplantation is the preferred treatment for patients with end-stage renal disease,
as it substantially increases a patient’s survival and is cost-saving compared to a lifetime of dialysis.
However, transplantation is not universally chosen by patients with renal failure, and limited knowledge
about the survival beneﬁt of transplantation versus dialysis may play a role. We created a mobile appli-
cation clinical decision aid called iChoose Kidney to improve access to individualized prognosis infor-
mation comparing dialysis and transplantation outcomes.
Methods: We describe the iChoose Kidney study, a randomized controlled trial designed to test the clinical
efﬁcacy of a mobile health decision aid among end-stage renal disease patients referred for kidney
transplantation at 3 large, diverse transplant centers across the United States. Approximately 450 patients
will be randomized to receive either (i) standard of care or “usual” transplantation education, or (ii)
standard of care plus iChoose Kidney.
Results: The primary outcome is change in knowledge about the survival beneﬁt of kidney transplantation
versus dialysis from baseline to immediate follow-up; secondary outcomes include change in treatment
preferences, improved decisional conﬂict, and increased access to kidney transplantation. Analyses are
also planned to examine effectiveness across subgroups of race, socioeconomic status, health literacy,
and health numeracy.
Discussion: Engaging patients in health care choices can increase patient empowerment and improve
knowledge and understanding of treatment choices. If the effectiveness of iChoose Kidney has a greater
impact on patients with low health literacy, lower socioeconomic status, and minority race, this decision
aid could help reduce disparities in access to kidney transplantation.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).F or the majority of the more than 600,000 patients inthe United States with end-stage renal disease
(ESRD),1 kidney transplantation is the preferred treat-
ment, providing longer survival, better quality of
life, lower hospitalization rates, and substantial cost
savings compared to dialysis.2,3
Patients who receive dialysis have an expected
remaining lifetime of 5.9 years versus 16.4 years
for transplant recipients, yet a large number of
patients have not actively pursued wait-listing for aspondence: Rachel E. Patzer, Emory University School of
ine, Division of Transplantation, 101 Woodruff Circle WMB
, Atlanta, Georgia 30322, USA. E-mail: rpatzer@emory.edu
ved 12 March 2016; revised 31 March 2016; accepted 3 April
published online 11 April 2016transplant.1 However, the relative risk of death varies
substantially depending on individual characteristics,
including age, race, or comorbidities.4 Prior studies
suggest that most patients want information about
treatment options andwant to participate in the selection
of treatment.5,6 However, current literature suggests
that ESRD patients have very limited knowledge about
their mortality rate on dialysis versus transplant, and
that not all patients are aware of the survival beneﬁt of
transplantation.7–9 In dialysis facilities, only 18% of
centers reported having detailed discussions about the
risks and beneﬁts of living- and deceased-donor trans-
plant.10 In addition, dialysis facility transplant educa-
tors have been found to need improved education on
the beneﬁts and process of renal transplantation.11
While transplant education ideally should start priorKidney International Reports (2016) 1, 34–42
RE Patzer et al.: Randomized Trial of Decision Aid: iChoose Kidney CLINICAL TRIAL: STUDY DESIGNto ESRD and referral to a transplant center, providing
information about the survival beneﬁt of transplant
versus dialysis, and in particular living- versus
deceased-donor transplant, could help to increase pa-
tients’ knowledge and preferences to get a transplant.
We previously developed and validated a novel,
shared patient–provider clinical decision aid called
iChoose Kidney (iPad, iPhone, and website: www.
ichoosekidney.emory.edu). iChoose Kidney is an elec-
tronic application that compares mortality on dialysis
versus kidney transplantation to translate medical evi-
dence into terms understandable to patients. Models of
mortality for patients receiving dialysis versus
deceased-donor (DD) or living-donor (LD) kidney
transplantation were developed using a cohort of more
than 700,000 patients in the nationally representative
United States Renal Data System (2000–2011 data).12 The
intention of this clinical decision aid is to help facilitate
patient–provider discussions about the risks and ben-
eﬁts of transplantation versus dialysis and to support
informed decision making among patients with ESRD.
While mobile health application production has
increased substantially in the last several years,13 with
more than 100,000 iOS and Android health-related
applications14,15 currently in the marketplace, few
methodologically rigorous studies have been conducted
to conﬁrm the efﬁcacy or effectiveness of mobile health
applications in improving access and outcomes of
health. To our knowledge, no studies have been con-
ducted to examine whether a mobile health application,
designed to inﬂuence the shared clinical decision-
making process between patient and provider to
choose a treatment option, inﬂuences knowledge about
treatment options and access to kidney transplantation.
The purpose of this paper is to describe the study
protocol used to design the iChoose Kidney randomized
controlled trial to test the clinical efﬁcacy of a clinical
decision aid in improving knowledge about the survival
beneﬁt of transplantation versus dialysis. We will also
examine secondary end points of decreased decisional
conﬂict in choosing treatment options for ESRD, chang-
ing treatment preference from dialysis to transplant, and
access to kidney transplantation. Planned subgroup an-
alyses will also examine whether the efﬁcacy of iChoose
Kidney varies by health literacy, numeracy, and race.
Finally, this study will seek to evaluate the usability of
the iChoose Kidney tool among clinical providers
(transplant nephrologists and surgeons).
MATERIALS AND METHODS
Study Overview
The iChoose Kidney Study is a 2-arm randomized trial to
test the efﬁcacy of amobile health clinical decision aid on
improving patient knowledge about the survival beneﬁtKidney International Reports (2016) 1, 34–42of transplantation versus dialysis. Prior to initiation of
study activities, the iChoose Kidney Study was regis-
tered on ClinicalTrials.gov (protocol NCT02235571).
This studywas approved by Institutional ReviewBoards
at Emory University, Columbia University, and North-
western University. All patients will be consented for
participation in the study before study involvement.
Target Population, Setting, and Inclusion and
Exclusion Criteria
The study will be conducted in 3 US kidney transplant
centers with a total target enrollment of 450 (150 at
each site): Emory Transplant Center in Atlanta, Geor-
gia, Columbia University Medical Center in New York,
New York, and Northwestern University Transplant
Center in Chicago, Illinois.
ESRD patients will be recruited into the study dur-
ing transplant medical evaluation if they meet inclusion
criteria: (i) 18 to 70 years of age; (ii) no previous solid
organ or multiorgan transplant; (iii) English speaking;
and (iv) no severe cognitive or visual impairment.
Study Arms
At kidney transplant evaluation, the control group will
receive the usual center-speciﬁc standard-of-care edu-
cation about renal transplantation, without the iChoose
Kidney decision aid. The intervention group will also
receive the usual center-speciﬁc standard-of-care edu-
cation. However, it will be supplemented by the use of
the iChoose Kidney decision aid (either iPad or iPhone
version). Among patients randomized to the interven-
tion study arm, a nephrologist or transplant surgeon
will use iChoose Kidney to provide individualized risk
estimates of mortality or survival by treatment (dialysis
vs. transplant; LD vs. DD transplant) based on a pa-
tient’s demographic and clinical characteristics. Using
visual displays, the iChoose Kidney decision aid com-
municates both absolute and relative risk estimates in
several messaging frames to increase patient and pro-
vider understanding of treatment beneﬁt (Figure 1).
The provider will have the option of which format to
display for the patient when discussing the risks and
beneﬁts of each treatment option.
Study Procedures
At each site, research assistants will identify patients
who meet inclusion criteria at the time of the patient’s
evaluation visit. Patients who agree to participate will
be provided with detailed study information, and
informed consent with written documentation will be
obtained from the research participant or appropriate
representative prior to initiation in the iChoose Kidney
Study. Research assistants will then generate study
identiﬁcation numbers for consented participants and35
Figure 1. Screenshots of the iChoose Kidney decision aid (iPad version), which communicate both absolute and relative risk estimates in
several messaging frames. By entering a patient’s clinical information (sex, age, race, ethnicity, time on dialysis, and several comorbidities), the
risk prediction calculator generates individualized 1- and 3-year mortality and survival risk estimates for (i) dialysis versus kidney transplant and
(ii) deceased- versus living-donor transplant.
CLINICAL TRIAL: STUDY DESIGN RE Patzer et al.: Randomized Trial of Decision Aid: iChoose Kidneyrandomize patients to 1 of 2 study arms (the inter-
vention arm or the control arm) with a random number
generator application via iPad or iPhone. Patients will
be surveyed on the same day before (baseline) and after
(follow-up) meeting with the provider, completing a
total of 2 surveys. Providers will take a baseline survey
prior to the start of the study, a follow-up survey
directly after meeting with each study patient, and a
ﬁnal poststudy completion survey (Figure 2). All pa-
tient and provider surveys will be administered
through SurveyMonkey, an electronic surveying tool
(or paper surveys later entered into SurveyMonkey if
Internet access is unavailable). Patients will be offered a
$10 gift card for their participation.
In the 2 months prior to initiation of the study, we
will conduct pilot testing among the 3 sites to ﬁnalize36study design and inform a power calculation. Pilot
testing of the study will enable us to modify any issues
with study design and data capture, and to ensure that
all sites are conducting and recording data uniformly.
Surveys
Provider Baseline Survey
Prior to using the iChoose tool in the RCT, providers
will be surveyed regarding their professional back-
ground and experience with educational tools (mobile
or other). Surveys will also assess the amount of time
providers spend with patients during evaluation ap-
pointments, how often they discuss survival beneﬁt of
transplant versus dialysis, and how they communicate
mortality risk with patients during the kidney pre-
transplant evaluation appointment.Kidney International Reports (2016) 1, 34–42
Figure 2. iChoose Kidney Study schema shows the study process and points of data collection for both control and intervention patients, and
clinical providers (i.e., nephrologists or surgeons). All patients will receive informed consent and a baseline survey before being evaluated by a
transplant provider. Patients will complete a postconsultation survey after the provider consultation. Providers will receive a baseline survey
prior to patient recruitment. After consulting with each patient, providers will take a postconsultation survey. At study completion, providers will
complete a poststudy survey.
RE Patzer et al.: Randomized Trial of Decision Aid: iChoose Kidney CLINICAL TRIAL: STUDY DESIGNPatient Baseline Survey
On the day of evaluation, research assistants will
administer baseline surveys to patients prior to the
commencement of their nephrology or transplant sur-
gery consultation. Baseline surveys include questions
about patient demographics, exposure to transplant
education, transplant knowledge, preferences for
treatment, and decisional conﬂict.
Provider Follow-up Survey
Directly following each nephrology or surgery trans-
plant evaluation, research assistants will administer a
short survey to providers to assess satisfaction with
and usefulness of the tool. Providers will report
whether or not they discussed the survival beneﬁt of
transplant versus dialysis and report other conversa-
tion topics. Providers who use the tool with inter-
vention patients will be asked whether they used
mortality or survival estimates. They will also re-
port whether they perceived that the patient gained
transplant knowledge through the use of the iChoose
Kidney tool. Providers who do not use the tool (if the
patient was a control, or for some other reason) will
be asked whether they felt their conversation with
the patient could have beneﬁted from using iChoose
Kidney.
Patient Follow-up Survey
Following the provider consultation, patients will be
given a follow-up survey, which consists of questions
similar to the baseline survey, including transplantKidney International Reports (2016) 1, 34–42knowledge, preferences of treatment, decisional con-
ﬂict, and health literacy and numeracy.
Provider Poststudy Survey
Within 1 month of study completion, providers will be
surveyed again on their conversations with patients
during the pretransplant evaluation and opinions on
the iChoose Kidney application. Speciﬁcally, they will
be asked about the average time spent during an
evaluation visit, how often they discuss survival
beneﬁt of transplant versus dialysis, words used to
communicate mortality risk, and perceived barriers to
using mobile technology. They will also be asked their
opinions of iChoose Kidney: its effect on patient
knowledge and uncertainty regarding treatment, chal-
lenges to using the tool, how it could be improved,
how it would best be used in practice (e.g., the time
point when it should be used, who should administer
it, which patients would beneﬁt most), and whether
they intend to use it in the future.
Outcome Measures
Transplant Knowledge
The primary outcome of the iChoose Kidney Study is
change in patient knowledge about the survival ben-
eﬁts of transplantation. Improvement in knowledge
will be measured using 8 survey questions in the pre-
and postassessment. First, patients will be asked 2
knowledge questions in the baseline and follow-up
survey: “On average, dialysis patients live: 1) longer
than transplant patients, 2) about the same time as37
CLINICAL TRIAL: STUDY DESIGN RE Patzer et al.: Randomized Trial of Decision Aid: iChoose Kidneytransplant patients, 3) a shorter time than transplant
patients, or 4) unsure”; and “On average, living donor
transplant patients live 1) a longer time than deceased
donor transplant patients, 2) about the same time as
deceased donor transplant patients, 3) a shorter time
than deceased donor transplant patients, or 4) unsure.”
Patients in both study arms will also be asked to esti-
mate their absolute chance of 3-year survival on dial-
ysis, transplant overall, deceased-donor transplant,
and living-donor transplant (4 items) both pre- and
postassessment. Lastly, patients will be asked to esti-
mate their relative risk of mortality with dialysis versus
kidney transplant (on a scale from 1 to 9) and whether
they are more, less, or equally likely to die with dial-
ysis compared to with a kidney transplant (2 items)
both pre- and postassessment.
Decisional Conﬂict
Decisional conﬂict was measured in both the pre- and
postsurvey by a validated scale of 10 items that assess
personal perceptions of uncertainty in choosing op-
tions, modiﬁable factors contributing to uncertainty,
and effective decision making (Table 1).16 This partic-
ular version of the decisional conﬂict scale was selected
for the study given its recommendation to be used on
individuals with “limited reading or response skills.”
The subscales for decisional conﬂict include uncer-
tainty (patient feels certain about choice), informed
status (patient informed of treatment options), values
clarity (patient clear regarding personal values), and
support (patient feels supported in decision making).
We used the scale to determine whether or not patients
had lower decisional conﬂict after using iChoose Kid-
ney during the evaluation appointment.
Patient Treatment Preferences
To assess whether the tool affected treatment prefer-
ences (from dialysis to kidney transplantation), patients
will be asked in both the pre- and postsurvey whatTable 1. Description of scales and tests administered to patients, pre– a
Item Description of purpose
Knowledge of survival beneﬁt To assess patient knowledge of survival beneﬁt of treatment
options (dialysis, deceased-donor transplant, and living-dono
transplant), patient-reported survival estimates of each
treatment, and relative risk of mortality with dialysis versus
transplant
Decisional conﬂict scale16 To assess personal perceptions of uncertainty in choosing
options, modiﬁable factors contributing to uncertainty, and
effective decision making
Patient treatment preferences To assess treatment preferences for end-stage renal disease
Newest Vital Signs17 To assess general literacy and numeracy skills as applied to
health information, yielding an overall estimate of health literacy
Lipkus numeracy test18 To assess numeracy, or the ability to understand and use numeric
information
38type of treatment they prefer for their kidney disease
(hemodialysis, peritoneal dialysis, transplant, or un-
sure). Participants will also be asked whether they
want a kidney transplant (yes or no) (Table 1).
Provider Opinions
We will use qualitative and quantitative methods to
assess provider preferences, opinions, and satisfaction
in order to evaluate usability of the iChoose Kidney tool
among providers. We will also compare providers’
intent to use mobile technology and the length of time
providers report discussing the survival beneﬁt of
transplant versus dialysis pre- versus poststudy.
Access to Transplant
Transplant access is a combined end point measured as
completion of the transplant evaluation, number of
living-donor inquiries, and wait-listing or transplant
receipt. We will collect information on these measures
from the patient medical record through data extrac-
tion at 6 months and 1 year from the patient’s evalu-
ation appointment. Variables collected will include
dates relevant to the transplant process (evaluation
start and end date, wait-listing date, and transplant
date) and whether the patient received a living-donor
inquiry since evaluation (Table 2).
Other Covariates
Patient Factors
We will collect the following demographic, socioeco-
nomic, and clinical variables from patient surveys: age,
race, sex, income, marital status, education level, health
insurance, time on dialysis, dialysis type, self-rated
health, and Internet access. A clinical data warehouse
for all 3 transplant centers will be used to collect data
on patient race, Hispanic ethnicity, age, body mass
index, history of comorbidities (diabetes, hypertension,
cardiovascular disease), low albumin level (<3.5 g/dl),
and dialysis start date. Research assistants will alsond post–provider consultation
How measured Number of items
r
Patient baseline and follow-up survey; scored on a scale by
assessing whether survival beneﬁt questions were correct or
incorrect
8
Patient baseline and follow-up surveys, and scored on a scale
from 1 to 100
10
Patient baseline and follow-up surveys; patients asked what type
of treatment they prefer and whether they want a kidney
transplant (yes or no)
2
Patient follow-up survey; patients given a nutrition label and asked
a series of free-response questions; responses scored and
categorized into low, medium, or high literacy
6
Patient baseline survey; scored on a scale from 1 to 11 and
categorized into low, medium, or high
11
Kidney International Reports (2016) 1, 34–42













Patient demographic and socioeconomic factors
Age x
Race x x x
Hispanic ethnicity x x x








Social support x x
Health literacy x
Health numeracy x
Prior exposure to transplant x
Time point ﬁrst educated about transplant x
Patient clinical factors
Body mass index x
History of hypertension x
History of diabetes x
History of cardiovascular disease x
Low albumin levels x
Date of dialysis start x
Time on dialysis x x
Dialysis modality x x
Outcome measures
Knowledge about transplant x
Decisional conﬂict x
Treatment preferences x
Access to transplant measures
Date of transplant evaluation x
Transplant evaluation end date x
Date of wait-listing x
Date of transplant x
Number of living-donor inquiries x
All variables collected were measures at the time of kidney transplant evaluation.
EMR, electronic medical record.
RE Patzer et al.: Randomized Trial of Decision Aid: iChoose Kidney CLINICAL TRIAL: STUDY DESIGNtrack whether patients had a social support member
with them at the evaluation appointment (Table 2).
Prior Exposure to Transplant
Patients will be asked to check a list of several ways
that they may have been exposed to information about
transplant (e.g., through brochures, websites, by
attending kidney support groups, etc.). They will also
be asked when they were ﬁrst educated about trans-
plant as a treatment option (Table 2).
Health Literacy and Numeracy
Health literacy will be measured using the Newest Vital
Signs assessment17 (6 items), and numeracy will be
assessed using the Lipkus test18 (11 items) (Table 1). To
administer Newest Vital Signs, patients will be given aKidney International Reports (2016) 1, 34–42nutrition label and asked a series of free-response
questions. Responses will then be scored and catego-
rized into low, medium, or high literacy. The Lipkus
test assesses the patient’s ability to understand and use
numeric information, and includes questions on risks
and percentages. Numeracy will be scored continu-
ously on a scale from 1 to 11.
Provider Factors
The following provider factors will be collected: time
practicing medicine or surgery, use of patient educa-
tional tools, perceived barriers to using mobile tech-
nology, average time spent during an evaluation visit,
how often the survival beneﬁt of transplant versus
dialysis is discussed, and speciﬁc reasons why the
provider might not discuss the survival beneﬁt of
transplant versus dialysis.
Data Management
Research assistants will track study participants uni-
formly across sites, using a worksheet they will later
transcribe into a Microsoft Excel spreadsheet. Patient
demographics, social support, and any deviations from
the study protocol will be recorded in this spreadsheet
(e.g., if the provider performed the intervention with a
control patient). At each site, patient demographics
(race, age, sex, ethnicity), dialysis start date, and
comorbidities included in the iChoose Kidney applica-
tion will be abstracted or extracted from patient
electronic medical records. To ensure data accuracy,
self-reported patient survey data will be compared to
data collected from electronic medical records.
The limited de-identiﬁed electronic medical record–
collected data from all 3 sites, as well the de-identiﬁed
SurveyMonkey patient and provider survey data, will
be merged, cleaned, and operationalized at Emory
University. Microsoft Excel and SAS 9.4 (SAS Institute,




All analyses will be conducted using an intention-to-
treat approach where patients will remain assigned to
the treatment condition they were randomized to
regardless of whether they receive the intervention
(e.g., patients randomized to the intervention arm but
who did not receive the iChoose Kidney clinical
decision aid will still be considered as intervention
participants). Descriptive analyses of transplant center–
level baseline variables (demographic and clinical
characteristics and transplant access measures) will be
compared. To evaluate the differences between study
arms at baseline, Pearson’s c2 tests and t-tests, or their
non-parametric equivalents, will be performed for39
CLINICAL TRIAL: STUDY DESIGN RE Patzer et al.: Randomized Trial of Decision Aid: iChoose Kidneycategorical and continuous variables, respectively.
Statistically signiﬁcant differences in baseline charac-
teristics will be adjusted when assessing the overall
intervention effect as described above.
Change in Knowledge
To assess change in knowledge from pre- to
postassessment, the change in score from the knowl-
edge questions will be calculated for each patient. A
paired t-test will be used to determine whether this
difference in proportions is signiﬁcant in intervention
versus control patients.
Change in Decisional Conﬂict
Each of 10 items in the decisional conﬂict scale will be
given a value of 0, 2, or 4 for responses “yes,” “no,” or
“unsure,” respectively. The items will then be sum-
med, divided by 10, and multiplied by 25 to determine
the total score of the decisional conﬂict variable.
Decisional conﬂict will then be scored on a scale from
0 (no decisional conﬂict) to 100 (high decisional con-
ﬂict) (Table 1). The change in decisional conﬂict will be
calculated for each patient from pre– to post–provider
consultation to determine whether the change is
signiﬁcantly higher in intervention patients versus
control patients using a c2 test or multivariable logistic
regression.
Change in Treatment Preferences
We will calculate the proportion of patients who
initially preferred dialysis to transplantation but
changed to transplantation during the postsurvey. A
c2 test will be used to determine whether this difference
is signiﬁcant in intervention versus control patients.
Access to Transplant
We will create a composite measure of living-donor
inquiries, placement on the wait list, and receipt of
transplant to determine long-term outcomes at 1 year
after inclusion in the study. We will use c2 tests or
multivariable logistic regression to determine whether
positive outcomes are signiﬁcantly different among
intervention patients versus control patients.
Planned Subgroup Analyses
To determine whether the effect of iChoose Kidney
varies by health literacy, numeracy, and race, we will
conduct similar analyses for knowledge and decisional
conﬂict but across different subgroups of patients.
Provider Attitudes
To evaluate whether providers believe the tool
impacted study patients, we will use descriptive ana-
lyses to assess variables collected directly after the
patient appointment. We will use c2 tests to assess
whether there was a difference in the number of
times providers had the conversation about the sur-
vival beneﬁt of transplant versus dialysis, and of40living- versus deceased-donor transplants with inter-
vention versus control patients. We will also compare
differences between provider responses at baseline and
poststudy regarding use of mobile decision aids in gen-
eral and intention to use iChoose Kidney using c2 tests.
Power and Sample Size Calculations
Sample size calculations will be based on our primary
aim to improve patient knowledge about the survival
beneﬁt of transplantation versus dialysis. To test the
primary null hypothesis of no difference in referral
proportions between the control and intervention
groups, a sample size of 450 patients (225 patients per
study arm) achieves 80% power to detect a moderate
knowledge difference of 13% between the 2 groups at
5% signiﬁcance level.
DISCUSSION
Critically important treatment decisions are often made
without evidence-based information about a patient’s
prognosis. Typically, average, population-based, non-
tailored prognosis estimates of mortality on dialysis
versus transplant are the only types of estimates
communicated to individual ESRD patients, if these
estimates are communicated at all.19 Despite over-
whelming evidence to support transplantation for
certain ESRD patients,20 patient-speciﬁc prognostic
information is rarely used to calculate a patient’s
individualized prognosis.21 The iChoose Kidney clinical
decision aid12 is a tool that clinical providers, including
nephrologists, surgeons, and other ESRD educators,
could potentially use with patients to explain their
chance of mortality or survival on dialysis versus
transplant, ultimately helping to facilitate more
informed decision making among ESRD patients about
their treatment options. However, prior to dissemina-
tion for use in a clinical setting, the efﬁcacy of the
clinical decision aid in improving patient knowledge
about the survival beneﬁt of transplantation is needed.
While transplantation is the preferred treatment for
most ESRD patients, signiﬁcant barriers exist in access
to multiple steps of the kidney transplantation process.
Patients who are minorities, of lower socioeconomic
status,22 and of lower health literacy23 are less likely to
receive a kidney transplant. Education about trans-
plantation as a treatment option may also play a role in
disparities in access to kidney transplantation. Ac-
cording to the US Agency for Healthcare Research and
Quality, disparities in health outcomes are due, in part,
to differences in access to health care, provider biases,
poor patient–provider communication, and poor health
literacy.24 Mobile health technology can be a useful
way to deliver interventions and may have a high
potential for reducing health disparities. Effective riskKidney International Reports (2016) 1, 34–42
RE Patzer et al.: Randomized Trial of Decision Aid: iChoose Kidney CLINICAL TRIAL: STUDY DESIGNcommunication strategies must consider patients with
varying degrees of health literacy, numeracy, and ed-
ucation levels to ensure that the information provided
by the tool is relevant and understandable to patients
from diverse backgrounds. The iChoose Kidney deci-
sion aid communicates risks of mortality on dialysis
versus transplant in both absolute and relative terms to
meet best practices in conveying health risks.25
Evidence-based research supports presenting absolute
risk in visuals to emphasize the clinical signiﬁcance and
size of risks,26 which iChoose Kidney utilizes.
Upon completion of this research, we will have
assessed the effect of a decision aid in improving
knowledge about the survival beneﬁts of kidney
transplantation versus dialysis. We will also have
assessed providers’ attitudes toward clinical decision
tools and their impact on the patient–provider inter-
action. If found to be effective in improving knowledge
about the survival beneﬁt of transplant, the clinical
decision aid could be a useful tool for improving access
to transplantation and improving decisional conﬂict
with regard to treatment options.
A strength of this randomized controlled trial is the
conduct of the research among a diverse, multicenter
population of ESRD patients, as results may be broadly
generalizable to other ESRD patients who have been
referred for transplantation to the more than 250
transplant centers across the United States. Further,
with additional testing in a population of incident ESRD
patients, the iChoose Kidney decision aid may also be
applicable for use across the more than 5000 dialysis
facilities or chronic kidney disease clinics in the United
States. Future studies could also assess the applicability
of the use of such a tool outside of the United States.
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